INCA033890-303: A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Condition: Colorectal Cancer

Sponsor: Incyte Corporation

Full Title
Protocol INCA033890-303: A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Study Treatment
INCA33890, a TGFBR2xPD-L1 bispecific antibody given in combination with the FOLFOX chemotherapy regimen and bevacizumab. 

Eligibility/Info
Participants must have stage IV colorectal cancer that is mismatch repair proficient and has not yet been treated in the advanced/metastatic setting.  

Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: 631-675-5075
HALO Messaging App: "Research Team"

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Nostrand Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology

Go To Trial Homepage